Dr. Michael Sulewski

Peter A. Campochiaro, M.D. is the George S. and Dolores Doré Eccles Professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins University School of Medicine. He is a clinician-scientist who directs a research laboratory and conducts clinical trials. His laboratory research is directed at understanding the pathogenesis of ocular neovascularization and excessive retinal vascular permeability, and the mechanism of cone cell death in inherited retinal degenerations. He helped to determine the importance of vascular endothelial growth factor (VEGF), hypoxia-inducible factor-1, and Tie2 in retinal and choroidal vascular diseases. The clinical trial group under Dr. Campochairo provided the first demonstration of the benefits of suppression of VEGF in diabetic macular edema and retinal vein occlusion. He has developed strategies for sustained suppression of VEGF that are currently being tested in clinical trials. Dr. Campochiaro trained at the University of Notre Dame, Johns Hopkins School of Medicine, and the University of Virginia. He did a vitreoretinal fellowship and research fellowships at Johns Hopkins and joined the faculty of the University of Virginia in 1984. He became professor of Ophthalmology and Neuroscience at the Wilmer Eye Institute, Johns Hopkins in 1991. Dr. Campochiaro is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Retinal Vein Occlusion, Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Trabeculectomy, and Vitrectomy. Dr. Campochiaro is board certified in American Board Of Ophthalmology.

Dr. Neil Bressler has been a member of the Wilmer Eye Institute's faculty since 1988 and is the inaugural James P. Gills Professor of Ophthalmology. He specializes in retinal diseases, with special interests in diabetic retinopathy and macular degeneration. Dr. Bressler's main research interests have been collaborative efforts in clinical trials of common retinal diseases, including age-related macular degeneration and diabetic retinopathy, having chaired several NIH-sponsored and industry-sponsored multicenter randomized clinical trials and authored almost 300 peer-reviewed publications. He is a past chair of the NIH-sponsored Diabetic Retinopathy Clinical Research Network, and was responsible for guidelines, policies, protocol development as well as implementation, and to facilitate Network operations in a way that maintains academic integrity and optimal clinical trial performance. He also has chaired the National Eye Institutes Data and Safety Monitoring Committee for intramural clinical trials and the FDA Ophthalmic Devices Panel. Dr. Bressler is currently editor-in-chief of JAMA Ophthalmology. Dr. Bressler is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Diabetic Macular Edema (DME), Age-Related Macular Degeneration (ARMD), Late-Onset Retinal Degeneration, Vitrectomy, and Cataract Removal. Dr. Bressler is board certified in American Board Of Ophthalmology.

Mandeep S. Singh, M.D., Ph.D., is associate professor of ophthalmology and genetic medicine in the Retina Division of the Wilmer Eye Institute and the recipient of the 2023 Andreas C. Dracopoulos Professorship in Ophthalmology. Dr. Singh is a retinal specialist. He is Co-Director of the Genetic Eye Disease (GEDi) Center, and is a principal investigator at the Center for Stem Cells and Ocular Regenerative Medicine (STORM). Dr. Singh completed his medical degree at the National University of Singapore. In 2009, he was elected to the Fellow of the Royal College of Surgeons of Edinburgh. He earned a PhD in ophthalmology from the University of Oxford, United Kingdom, in 2014. He completed fellowships in vitreoretinal diseases and surgery at the Oxford Eye Hospital and Moorfields Eye Hospital, both in the United Kingdom. His clinical expertise includes surgical, medical and genetic conditions of the retina and macula. Dr. Singh is specialty-trained in vitrectomy surgery for retinal detachment, macular holes, macular pucker, epiretinal membrane, proliferative vitreoretinopathy, complex retinal detachments including reoperations, vitreous hemorrhage removal, and other retinal surgeries. He also specializes in age-related macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, and choroidal neovascularization. Dr. Singh sees patients and families with genetic retinal diseases such as retinitis pigmentosa, Usher syndrome, Stargardt disease and macular dystrophies. His research focus is retinal stem cell transplantation. Dr. Singh’s work has been recognized through the Eye Institute–Allergan Research Prize, the Merton College University of Oxford Graduate Prize Scholarship, the Oxford Ophthalmological Congress Founder’s Cup and Medal, the Ruskell Medal, the Johns Hopkins Clinician Scientist Award, and the Bert M. Glaser, MD Award for Innovative Research in Retina. He is a member of the American Academy of Ophthalmology and the Association for Research in Vision and Ophthalmology. He is also a member of the Club Jules Gonin and the Macula Society. CV https://www.hopkinsmedicine.org/-/media/wilmer/documents/cvs/Singh_CV.pdf. Dr. Singh is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Retinitis Pigmentosa, Stargardt Macular Degeneration, Late-Onset Retinal Degeneration, Retinopathy Pigmentary Mental Retardation, and Vitrectomy.